Blood tests can now detect Alzheimer’s disease years before a single symptom appears. The FDA cleared the first such test in 2025, and healthcare systems are rolling them into routine practice. For anyone with a family history of Alzheimer’s, this changes the conversation with your doctor entirely.
How Biomarkers Signal Brain Decline
Three proteins do most of the diagnostic work, each reflecting a different layer of what is happening in the brain.
p-tau217 rises as tau tangles begin forming, often the earliest measurable signal. The amyloid-beta 42/40 ratio reflects plaque accumulation, with lower ratios suggesting more buildup. Neurofilament light chain tracks how fast nerve cell damage is progressing.
p-tau217 can flag risk even before PET scans show abnormalities, which themselves detect changes 10 to 20 years before symptoms appear. In one cohort of 317 cognitively healthy adults tracked for eight years, higher p-tau217 levels predicted Alzheimer’s-related changes faster than peers with lower levels. The biomarker flagged people who later became amyloid-positive even when their initial scans appeared normal.
What Earlier Detection Could Mean
Detecting disease years before symptoms creates real options. New disease-modifying therapies work better when given early, before substantial neuronal loss. Families also gain time for legal, financial, and caregiving decisions that become far harder once cognition slips.
A positive biomarker result indicates elevated risk and pathology, not a fixed timeline. Some people with abnormal markers progress quickly; others remain cognitively stable for years. The science has arrived faster than the surrounding infrastructure of counseling and policy. That gap is where the next two years will matter most.
